ESC 365 - Rationale behind development of novel drugs for atrial arrhythmias

EHRA Premium Access

Rationale behind development of novel drugs for atrial arrhythmias

Session: Critical appraisal of antiarrhythmic drug therapy - The science behind trial-and-error

Topic: Arrhythmias

Speaker: Professor J. Heijman (Graz, AT)

Event: EHRA 2019

Congress Presentation

About the speaker

Professor Jordi Heijman

Medical University of Graz, Graz (Austria)

9 presentations

3 followers

4 more presentations in this session

The trials-and-errors of antiarrhythmic drug therapy

Speaker: Professor J. Camm (London, GB)

Genetic basis for tailored drug therapy for ventricular arrhythmias

Speaker: Associate Professor C. Remme (Amsterdam, NL)

Antiarrhythmic drugs - What, why, when to whom

Speaker: Professor G. Dan (Bucharest, RO)

Panel discussion

Access the full session

Critical appraisal of antiarrhythmic drug therapy - The science behind trial-and-error

Speakers: Professor J. Heijman, Professor J. Camm, Associate Professor C. Remme, Professor G. Dan

About the event

EHRA 2019

17 March - 19 March 2019

Sessions Presentations

Congress

ESC 365 is supported by